On January 12, 2024, Arena BioWorks announced its launch as a biomedical research institute with a mission to uncover mechanisms of disease by engaging in basic biological research that will be translated into lifesaving biotech therapeutics. Arena BioWorks is a dual-purpose entity aimed at achieving social good and creating long-term sustainable impact through the formation of for-profit biotechnology companies. Wilson Sonsini Goodrich & Rosati is advising Arena BioWorks on patent and transactional matters.

As part of its novel model, discovery and company creation will occur seamlessly under one roof. By relying solely on private funding, Arena will be able to quickly translate insight into discovery, distinguishing it from traditional models. Arena will support development efforts with its drug discovery platforms through preclinical studies and beyond, when appropriate.

The Wilson Sonsini team advising Arena BioWorks on patent and transactional matters is led by Lou Lieto and Farah Gerdes and included Rachna Ujwal and Lillian Li.

For more information, please see Arena BioWorks' press release. Additional coverage can be found on The New York Times.